LITTLE ROCK, Ark.--(BUSINESS WIRE)--Vivione Biosciences Inc. (“Vivione”) (TSX:VBI), through its wholly owned subsidiary, Vivione Biosciences, LLC, is pleased to announce that Ardour Capital has been selected as the exclusive investment banker to Vivione Biosciences, Inc. for its $10 million equity raise.
Ardour Capital Investments, LLC provides investment banking and security brokerage services to a variety of organizations. The firm offers a host of services including equity and debt financing, merger and acquisition, exchange listing, project finance, warrant conversion advisory, as well as business plan preparation and review, valuation analyses and strategic planning services focusing on small capitalization growth companies. Ardour Capital Investments, LLC was founded in 2002 and is headquartered in New York City, New York.
"After interviewing numerous investment banking firms and a significant amount of due diligence, we are extremely pleased to be working with Ardour Capital," said Kevin Kuykendall, Chairman and CEO of Vivione Biosciences. "We are impressed with the Ardour team and very excited to be working with a group who understands our company and the opportunity before us."
Vivione’s RAPID-B system provides a universal platform that allows companies to rapidly detect and evaluate solutions for microbial contamination within the food, bio-therapeutics, clinical and oil and gas industries. This system provides companies with real-time diagnostics which quickly and accurately identify and enumerate pathogens in different products and environments.
Vivione is a TSX Venture Exchange listed biosciences company focused on the commercialization of its proprietary RAPID-B system; an integrated system of hardware, software and chemical reagents that quickly and accurately identify, quantify and qualify bacteria and other pathogens in food safety, bio-therapeutics, clinical, industrial and oil & gas environments. For more information, visit www.VivioneBiosciences.com.
This news release contains "forward-looking statements" within the meaning of applicable securities laws. Although Vivione believes that the expectations reflected in its forward-looking statements are reasonable, such statements have been based on factors and assumptions concerning future events that may prove to be inaccurate. These factors and assumptions are based upon currently available information to Vivione. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. This news release contains forward-looking information relating to the commercialization and the development of the RAPID-B system, Vivione’s business and growth strategy and the commercialization and the development of the Molecular Design technology. Readers are cautioned to not place undue reliance on forward-looking statements. The statements in this news release are made as of the date of this news release and, except as required by applicable law, Vivione does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. Vivione undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Vivione, or its financial or operating results or (as applicable), their securities.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.